Daiichi Sankyo Company, Limited

Atsushi Urano

Jun Hasegawa

Toshinori Agatsuma

Toshiaki Ohtsuka

Takeshi Takizawa

Tatsuji Matsuoka

Yasuki Kamai

Takako Kimura

Yumi Matsui

Chigusa Yoshimura

Reimi Kawaida

Kaori Nakahara

Junko Yamaguchi

Kenji Murakami

Keisuke Fukuchi

Shu Takahashi

Kenji Hirotani

Mitsuhiro Yazawa

The present invention provides a combination of an antibody binding to a fibroblast growth factor receptor, and another agent.

Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor

The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Anti-FGFR2 antibodies and methods of use thereof for treating cancer

Anti-FGFR2 antibodies and pharmaceutical compositions thereof

An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment.

Anti B7-H3 antibody

The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Anti-EPHA2 antibody

Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Growing community of inventors

Tokyo, Japan

Atsushi Urano